ARCHIVES

NCI Places Hold On Genentech Drug Trials, Citing Disagreement Over Intellectual Property Provisions.

This article is from The Cancer Letter archive.

Vol. 36 No. 09 | March 12, 2010

Download PDF Visit The Full Archive

Related Articles

Study: Blood Test More Accurate Than Traditional Tumor Biopsy

April 26, 2013

UPCI Clarifies Agreement Between Eli Lilly And PCRN.

July 27, 2001

FDA, NCI Seek Compromise On Survival Endpoints

June 16, 1989

Chemoprevention Clinical Trial RFA Being Developed For January Concept Review, Along With “Bridge” RFA

November 27, 1981

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

Congress Nearing Final Action On Appropriations, But Potential GRH Cuts Leaves Outlook Unclear

September 12, 1986